Pfizer announces top-line results from a Phase 3 long-term safety study of ALO-02
11 October 2012 | By Pfizer
“These top-line data provide evidence of the long-term safety of ALO-02..."
List view / Grid view
11 October 2012 | By Pfizer
“These top-line data provide evidence of the long-term safety of ALO-02..."
11 October 2012 | By Merck
World Health Organization commends the MECTIZAN® Donation Program on its contribution to near-elimination of river blindness from the Western Hemisphere...
10 October 2012 | By Novartis
New data to be presented...
10 October 2012 | By ANDREW LLOYD & ASSOCIATES
New plant on its Mourenx, France site to produce a large volume commercial API...
The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) under current Good Manufacturing Practices (cGMP). The production of clinical grade iPSCs is considered a critical component to realizing the therapeutic potential of pluripotent stem…
10 October 2012 | By Biogen Idec
Extensive data from MS franchise...
10 October 2012 | By Pfizer
In 2050, the number of people aged 60+ years worldwide will increase to nearly 2 billion...
9 October 2012 | By GlaxoSmithKline
GSK welcomes the announcement from GAVI Alliance...
9 October 2012 | By Merck
Merck has announced plans to move the company's global headquarters within the state...
9 October 2012 | By Sanofi
Sanofi announced the launch by Sanofi India Limited of AllStar™...
9 October 2012 | By Genzyme
New data from Genzyme’s clinical development programs...
8 October 2012 | By Azbil BioVigilant
Leiter Rx will utilize Azbil BioVigilant’s IMD-A® 300-series systems...
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).
8 October 2012 | By AstraZeneca
AstraZeneca and Ardelyx announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme...
8 October 2012 | By Teva Pharmaceutical Industries Ltd
Key data from the Company’s MS franchise...